NCT07476326 Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma Status NOT_YET_RECRUITING Phase PHASE1
NCT07176650 Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma Status RECRUITING Phase PHASE1
NCT06640530 Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06304597 Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy Status NOT_YET_RECRUITING Phase PHASE1
NCT06112808 A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05004025 Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Status COMPLETED Phase PHASE1
NCT04875611 Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment Status RECRUITING Phase PHASE2
NCT04627012 Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma Status COMPLETED Phase N/A
NCT03245021 Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03181308 Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC Status COMPLETED Phase PHASE1
NCT03029780 An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma Status COMPLETED Phase PHASE2
NCT02842125 Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer Status TERMINATED Phase PHASE1/PHASE2